Angiotensin‐converting enzyme inhibitors prevent liver‐related events in nonalcoholic fatty liver disease
Xinrong Zhang(Tianjin Medical University), Vincent Wai‐Sun Wong(Chinese University of Hong Kong), Jimmy Che‐To Lai(Chinese University of Hong Kong), Lilian Yan Liang(Chinese University of Hong Kong), Guan‐Lin Li(Chinese University of Hong Kong), Vicki Wing‐Ki Hui(Chinese University of Hong Kong), Grace Lai‐Hung Wong(Chinese University of Hong Kong), Huapeng Lin(Chinese University of Hong Kong), Henry Lik‐Yuen Chan(Chinese University of Hong Kong), Yee‐Kit Tse(Chinese University of Hong Kong), Terry Cheuk‐Fung Yip(Chinese University of Hong Kong)
Cited by 91
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
|Journal of Hepatology|2024|1.6k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Annals of Hepatology|2023|789
Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients
|Proceedings of the National Academy of Sciences|2015|755